These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

525 related items for PubMed ID: 16156861

  • 1. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW.
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 4. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 15; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 5. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS.
    Leukemia; 2003 Feb 15; 17(2):451-7. PubMed ID: 12592346
    [Abstract] [Full Text] [Related]

  • 6. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
    Morgan MA, Wegner J, Aydilek E, Ganser A, Reuter CW.
    Leukemia; 2003 Aug 15; 17(8):1508-20. PubMed ID: 12886237
    [Abstract] [Full Text] [Related]

  • 7. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM.
    Oncogene; 2002 Nov 07; 21(51):7883-90. PubMed ID: 12420225
    [Abstract] [Full Text] [Related]

  • 8. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM, Hamilton AD.
    Oncogene; 2000 Dec 27; 19(56):6584-93. PubMed ID: 11426643
    [Abstract] [Full Text] [Related]

  • 9. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome.
    Efuet ET, Keyomarsi K.
    Cancer Res; 2006 Jan 15; 66(2):1040-51. PubMed ID: 16424040
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells.
    Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC.
    Anticancer Res; 2000 Jan 15; 20(4):2761-71. PubMed ID: 10953355
    [Abstract] [Full Text] [Related]

  • 11. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 12. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
    Du W, Prendergast GC.
    Cancer Res; 1999 Nov 01; 59(21):5492-6. PubMed ID: 10554025
    [Abstract] [Full Text] [Related]

  • 13. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells.
    Mazet JL, Padieu M, Osman H, Maume G, Mailliet P, Dereu N, Hamilton AD, Lavelle F, Sebti SM, Maume BF.
    FEBS Lett; 1999 Oct 29; 460(2):235-40. PubMed ID: 10544242
    [Abstract] [Full Text] [Related]

  • 14. Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase.
    Mattingly RR, Gibbs RA, Menard RE, Reiners JJ.
    J Pharmacol Exp Ther; 2002 Oct 29; 303(1):74-81. PubMed ID: 12235235
    [Abstract] [Full Text] [Related]

  • 15. Requirement of c-jun N-terminal kinase for apoptotic cell death induced by farnesyltransferase inhibitor, farnesylamine, in human pancreatic cancer cells.
    Mizukami Y, Ura H, Obara T, Habiro A, Izawa T, Osanai M, Yanagawa N, Tanno S, Kohgo Y.
    Biochem Biophys Res Commun; 2001 Oct 19; 288(1):198-204. PubMed ID: 11594773
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
    Ghosh PM, Ghosh-Choudhury N, Moyer ML, Mott GE, Thomas CA, Foster BA, Greenberg NM, Kreisberg JI.
    Oncogene; 1999 Jul 15; 18(28):4120-30. PubMed ID: 10435593
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
    Lerner EC, Hamilton AD, Sebti SM.
    Anticancer Drug Des; 1997 Jun 15; 12(4):229-38. PubMed ID: 9199657
    [Abstract] [Full Text] [Related]

  • 19. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
    Wittrock J, Schweizer P, Girgert R.
    Anticancer Res; 2002 Jun 15; 22(6C):4205-9. PubMed ID: 12553057
    [Abstract] [Full Text] [Related]

  • 20. Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone.
    Lau CP, Huang L, Tsui SK, Ng PK, Leung PY, Kumta SM.
    J Orthop Res; 2011 Mar 15; 29(3):403-13. PubMed ID: 20886653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.